Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA vs MAL PDT in Superficial Basal Cell Carcinoma
NCT01491711Phase 4Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of aminolevulinic acid 10% gel in basal cell carcinoma (BCC) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Treatment failure at 12 months. Status: unknown.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT01491711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491711.